Advertisement

Central European Journal of Medicine

, Volume 9, Issue 2, pp 272–278 | Cite as

Adverse reaction of a combined treatment for unresectable liver cancer

Research Article

Abstract

To investigate the adverse reactions of transcatheter arterial chemoembolization (TACE) combined with trastuzumab in the treatment of unresectable live cancer, 85 unresectable liver cancer patients were treated with 35 mg epirubicin, with lipiodol and gelatin sponge granule as the embolic agent, and trastuzumab (4mg/kg) was administered intravenously. All the adverse reactions were investigated by blood routine examination and the checking of liver, renal and thyroid functions on the postoperative 2nd and 30th day. No patients died of direct medication. The main adverse reactions included haematological toxicity, liver function lesion and postoperative syndromes such as nausea, vomiting, fever and liver area aching. Two days after the treatment, the amount of the serum total bilirubin (TB) and white blood cell (WBC) increased dramatically, while platelet (PLT) changed a little, and creatinine (Cr) and blood urea nitrogen (BUN) did not change at all. Thirty days after the treatment, blood routine, liver and renal functions were examined, demonstrating that the liver function remained unchanged, PLT decreased apparently, WBC was lower, and Cr and BUN changed slightly compared to those before the treatment. The combined treatment is safe for unresectable liver cancer and thus can be used as a routine intervention method.

Keywords

Adverse effect Hepatoma cell Radioimmunotherapy Transcatheter arterial chemoembolization Trastuzumab 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Namboodiri A.M., Pandey J.P., Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes, Clin. Exp. Immunol., 2011, 166, 361–365PubMedCentralPubMedCrossRefGoogle Scholar
  2. [2]
    Kostyal D., Welt R.S., Danko J., Shay T., Lanning C., Horton K., et al., Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling, Med. Oncol., 2012, 29, 1486–1494PubMedCrossRefGoogle Scholar
  3. [3]
    Sawaki M., Mukai H., Tokudome N., Nakayama T., Taira N., Mizuno T., et al., Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study, Breast Cancer, 2012, 19, 253–258PubMedCrossRefGoogle Scholar
  4. [4]
    Abe H., Umeda T., Kawai Y., Tanaka M., Mori T., Cho H., et al., [Adjuvant trastuzumab can be infused safely over 30 minutes], Gan To Kagaku Ryoho, 2010, 37, 1887–1891PubMedGoogle Scholar
  5. [5]
    Fujita T., Doihara H., Kawasaki K., Takabatake D., Takahashi H., Washio K., et al., PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer, Br. J. Cancer, 2006, 94, 247–252PubMedCentralPubMedCrossRefGoogle Scholar
  6. [6]
    Perez E.A., Jenkins R.B., Dueck A.C., Wiktor A.E., Bedroske P.P., Anderson S.K., et al., C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial, J. Clin. Oncol., 2011, 29, 651–659PubMedCrossRefGoogle Scholar
  7. [7]
    Esteva F.J., Guo H., Zhang S., Santa-Maria C., Stone S., Lanchbury J.S., et al., PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer, Am. J. Pathol., 2010, 177, 1647–1656PubMedCrossRefGoogle Scholar
  8. [8]
    Todeschini P., Cocco E., Bellone S., Varughese J., Lin K., Carrara L., et al., Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab, Br. J. Cancer, 2011, 105, 1176–1182PubMedCentralPubMedCrossRefGoogle Scholar
  9. [9]
    Nagahisa Y., Imai S., Yamaguchi K., Okabe M., Tsuruta A., Kawamoto K., et al., [A case of liver metastasis of breast cancer responding to trastuzumab plus weekly paclitaxel chemotherapy maintaining CR for 30 months], Gan To Kagaku Ryoho, 2007, 34, 1501–1503PubMedGoogle Scholar
  10. [10]
    Horiguchi J., Oyama T., Takata D., Rokutanda N., Nagaoka R., Odawara H., et al., Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience, Anticancer Res., 2011, 31, 3041–3046PubMedGoogle Scholar
  11. [11]
    Takahashi T., Kochi M., Kanamori N., Kaiga T., Funada T., Fujii M., et al., [Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer-report of a case], Gan To Kagaku Ryoho, 2009, 36, 1885–1888PubMedGoogle Scholar
  12. [12]
    Yao Y., [Effects of Feiji decoction for soothing the liver combined with psychotherapy on quality of life in primary lung cancer patients], Zhongguo Fei Ai Za Zhi, 2012, 15, 27–33PubMedGoogle Scholar
  13. [13]
    Tada A., Ogawa M., Inagaki J., Horikoshi N., Inoue K., Yamazaki H., et al., [Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer], Gan To Kagaku Ryoho, 1986, 13, 70–74PubMedGoogle Scholar
  14. [14]
    Osako T., Ito Y., Takahashi S., Tokudome N., Iwase T., Hatake K., Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer, Cancer Chemother. Pharmacol., 2008, 62, 159–164PubMedCrossRefGoogle Scholar
  15. [15]
    Kimura M., Tominaga T., Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer, Breast Cancer, 2002, 9, 153–159PubMedCrossRefGoogle Scholar
  16. [16]
    Pectasides D., Pectasides E., Maintenance or consolidation therapy in advanced ovarian cancer, Oncology, 2006, 70, 315–324PubMedCrossRefGoogle Scholar
  17. [17]
    Zak Y., Rhoads K.F., Visser B.C., Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type, Arch. Surg., 2011, 146, 778–784PubMedCrossRefGoogle Scholar
  18. [18]
    Li B., Yu J., Wang L., Li C., Zhou T., Zhai L., Xing L., Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma, Am. J. Clin. Oncol., 2003, 26, e92–99PubMedGoogle Scholar
  19. [19]
    Sahara S., Kawai N., Sato M., Tanaka T., Ikoma A., Nakata K., et al., Prospective Evaluation of Transcatheter Arterial Chemoembolization (TACE) with Multiple Anti-Cancer Drugs (Epirubicin, Cisplatin, Mitomycin C, 5-Fluorouracil) Compared with TACE with Epirubicin for Treatment of Hepatocellular Carcinoma, Cardiovasc. Intervent. Radiol., 2012, doi: 10.1007/s00270-012-0352-xGoogle Scholar
  20. [20]
    Chen S., Li B., Xie H., Xu L., Niu G., Fan K., et al., Phase I clinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma, Cancer Biother. Radiopharm., 2004, 19, 589–600PubMedCrossRefGoogle Scholar
  21. [21]
    Wang S.E., Xiang B., Guix M., Olivares M.G., Parker J., Chung C.H., et al., Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab, Mol. Cell Biol., 2008, 28, 5605–5620PubMedCentralPubMedCrossRefGoogle Scholar
  22. [22]
    Yamaguchi K., Chijiiwa K., Torato N., Kinoshita M., Tanaka M., Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer, Am. J. Gastroenterol., 2000, 95, 1939–1945PubMedCrossRefGoogle Scholar
  23. [23]
    Le Brun-Ly V., Martin J., Venat-Bouvet L., Darodes N., Labourey J.L., Genet D., et al., Cardiac toxicity with capecitabine, vinorelbine and trastuzumab therapy: case report and review of fluoropyrimidinerelated cardiotoxicity, Oncology, 2009, 76, 322–325Google Scholar
  24. [24]
    Ritter C.O., Wartenberg M., Mottok A., Steger U., Goltz J.P., Hahn D., et al., Spontaneous liver rupture after treatment with drug-eluting beads, Cardiovasc. Intervent. Radiol., 2012, 35, 198–202PubMedCrossRefGoogle Scholar
  25. [25]
    Fromigue J., De Baere T., Baudin E., Dromain C., Leboulleux S., Schlumberger M., Chemoembolization for liver metastases from medullary thyroid carcinoma, J. Clin. Endocrinol. Metab., 2006, 91, 2496–2499PubMedCrossRefGoogle Scholar
  26. [26]
    Ruszniewski P., O’Toole D., Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors, Neuroendocrinology, 2004, 80(Suppl 1), 74–78PubMedCrossRefGoogle Scholar
  27. [27]
    Tu C.M., Chu K.M., Yang S.P., Cheng S.M., Wang W.B., Trastuzumab (Herceptin)-associated cardiomyopathy presented as new onset of complete left bundle-branch block mimicking acute coronary syndrome: a case report and literature review, Am. J. Emerg. Med., 2009, 27, e901–903Google Scholar
  28. [28]
    Yan X., Morgan J.P., Neuregulin1 as novel therapy for heart failure, Curr. Pharm. Des., 2011, 17, 1808–1817PubMedCrossRefGoogle Scholar
  29. [29]
    Peltier M., Houpe D., Cohen-Solal A., Beguin M., Levy F., Tribouilloy C., Treatment practices in heart failure with preserved left ventricular ejection fraction: a prospective observational study, Int. J. Cardiol., 2007, 118, 363–369PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of General SurgeryAffiliated Hospital of Inner Mongolia Medical UniversityHuhhotP.R.China
  2. 2.Biotech Pharmaceutical Co., LtdPekingP.R.China
  3. 3.Department of General SurgeryAffiliated Hospital of Inner Mongolia medical universityHuhhotP.R.China

Personalised recommendations